HomeProductsBioactive CompoundsGPCR & G Protein TargetsEndothelin ReceptorAtrasentan
Chemical structure of CAS 173937-91-2

Atrasentan

In Stock•Starting at $34 for 10 mg•Purity ≥ 95%
CAS No.173937-91-2
MDL No.N/A
MFC29H38N2O6
MW510.60
InChI KeyMOTJMGVDPWRKOC-QPVYNBJUSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
10 mg95%$34In Stock
50 mg95%$88In Stock
100 mg95%$101In Stock
250 mg95%$190In Stock
1 g99+%$530In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Atrasentan is a pyrrolidine derivative.

CAS No.173937-91-2
Product NameAtrasentan

Biological Targets

EDNRA

Associated Conditions

prostate adenocarcinoma·prostate cancer·kidney cancer·diabetic nephropathy·IGA glomerulonephritis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Atrasentan: First Approval.

Drugs • Vol. 85, Issue 10 • 2025
PMID: 40760295DOI: 10.1007/s40265-025-02208-7

Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis.

Clinical kidney journal • Vol. 18, Issue 3 • 2025
PMID: 40130231PMC: PMC11932335DOI: 10.1093/ckj/sfaf066

ALIGNing the treatment of IgA nephropathy: Reducing proteinuria with endothelin A receptor inhibition.

Med (New York, N.Y.) • Vol. 6, Issue 1 • 2025
PMID: 39798547DOI: 10.1016/j.medj.2024.11.017

Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • Vol. 40, Issue Supplement_1 • 2025
PMID: 39907539PMC: PMC11795649DOI: 10.1093/ndt/gfae214

Documentation

Similar Products